Sol-Gel Technologies (SLGL) EBT Margin (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly EBT Margin of 3569.44% for Q1 2026, up 268981.0% year-over-year from N/an in Q1 2025, and up 140.12% quarter-over-quarter from 8895.83% in Q4 2025.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) EBT Margin (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported EBT Margin for 9 consecutive years, with 3569.44% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 268981.0% year-over-year to 3569.44%; the TTM figure through Mar 2026 stood at 289.71% (up 9319.0% YoY), while the FY2025 annual figure was 340.63%, up 19502.0% from the prior year.
- EBT Margin rose to 3569.44% in Q1 2026 per SLGL's latest filing, from 8895.83% in the prior quarter.
- Across five years, EBT Margin topped out at 3569.44% in Q1 2026 and bottomed at 50899.0% in Q4 2022.
- Historically, EBT Margin has averaged 6287.59% across 5 years, with a median of 1098.82% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 5096412 bps — and 2023, when it jumped 3897081 bps.
- Sol-Gel Technologies' EBT Margin stood at 50899.0% in 2022, then soared by 77 bps to 11928.19% in 2023, then slumped by 69 bps to 20103.96% in 2024, then soared by 56 bps to 8895.83% in 2025, then soared by 140 bps to 3569.44% in 2026.
- Business Quant data shows SLGL's EBT Margin at 3569.44% in Q1 2026, 8895.83% in Q4 2025, and 1572.0% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | -785.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -785.62% |
| Mar 31, 2026 | 3,569.44% |
| Dec 31, 2025 | -490.09% |
| Sep 30, 2025 | -1,572.00% |
| Jun 30, 2025 | 62.86% |
| Mar 31, 2025 | 879.63% |
| Dec 31, 2024 | -2,193.88% |
| Sep 30, 2024 | -15.44% |
| Jun 30, 2024 | 23.41% |
| Mar 31, 2024 | 1,440.34% |
| Dec 31, 2023 | -1,209.62% |
| Sep 30, 2023 | -2,961.03% |
| Jun 30, 2023 | -1,192.59% |
| Mar 31, 2023 | 3,687.67% |
| Dec 31, 2022 | -6,205.00% |
| Sep 30, 2022 | -1,388.89% |
| Jun 30, 2022 | 3.81% |
| Mar 31, 2022 | 198,333.33% |
| Dec 31, 2021 | 67.08% |
| Sep 30, 2021 | 95.21% |